158 related articles for article (PubMed ID: 15958389)
1. Regulation of homeodomain-interacting protein kinase 2 (HIPK2) effector function through dynamic small ubiquitin-related modifier-1 (SUMO-1) modification.
Hofmann TG; Jaffray E; Stollberg N; Hay RT; Will H
J Biol Chem; 2005 Aug; 280(32):29224-32. PubMed ID: 15958389
[TBL] [Abstract][Full Text] [Related]
2. Covalent modification of human homeodomain interacting protein kinase 2 by SUMO-1 at lysine 25 affects its stability.
Gresko E; Möller A; Roscic A; Schmitz ML
Biochem Biophys Res Commun; 2005 Apr; 329(4):1293-9. PubMed ID: 15766567
[TBL] [Abstract][Full Text] [Related]
3. Role of the SUMO-interacting motif in HIPK2 targeting to the PML nuclear bodies and regulation of p53.
Sung KS; Lee YA; Kim ET; Lee SR; Ahn JH; Choi CY
Exp Cell Res; 2011 Apr; 317(7):1060-70. PubMed ID: 21192925
[TBL] [Abstract][Full Text] [Related]
4. Control of nuclear HIPK2 localization and function by a SUMO interaction motif.
de la Vega L; Fröbius K; Moreno R; Calzado MA; Geng H; Schmitz ML
Biochim Biophys Acta; 2011 Feb; 1813(2):283-97. PubMed ID: 21145359
[TBL] [Abstract][Full Text] [Related]
5. Covalent modification of the homeodomain-interacting protein kinase 2 (HIPK2) by the ubiquitin-like protein SUMO-1.
Kim YH; Choi CY; Kim Y
Proc Natl Acad Sci U S A; 1999 Oct; 96(22):12350-5. PubMed ID: 10535925
[TBL] [Abstract][Full Text] [Related]
6. The homeodomain-interacting kinase PKM (HIPK-2) modifies ND10 through both its kinase domain and a SUMO-1 interaction motif and alters the posttranslational modification of PML.
Engelhardt OG; Boutell C; Orr A; Ullrich E; Haller O; Everett RD
Exp Cell Res; 2003 Feb; 283(1):36-50. PubMed ID: 12565818
[TBL] [Abstract][Full Text] [Related]
7. HIPK2 regulates transforming growth factor-beta-induced c-Jun NH(2)-terminal kinase activation and apoptosis in human hepatoma cells.
Hofmann TG; Stollberg N; Schmitz ML; Will H
Cancer Res; 2003 Dec; 63(23):8271-7. PubMed ID: 14678985
[TBL] [Abstract][Full Text] [Related]
8. Requirement of the co-repressor homeodomain-interacting protein kinase 2 for ski-mediated inhibition of bone morphogenetic protein-induced transcriptional activation.
Harada J; Kokura K; Kanei-Ishii C; Nomura T; Khan MM; Kim Y; Ishii S
J Biol Chem; 2003 Oct; 278(40):38998-9005. PubMed ID: 12874272
[TBL] [Abstract][Full Text] [Related]
9. Desumoylation of homeodomain-interacting protein kinase 2 (HIPK2) through the cytoplasmic-nuclear shuttling of the SUMO-specific protease SENP1.
Kim YH; Sung KS; Lee SJ; Kim YO; Choi CY; Kim Y
FEBS Lett; 2005 Nov; 579(27):6272-8. PubMed ID: 16253240
[TBL] [Abstract][Full Text] [Related]
10. The Tyrosine Kinase c-Abl Promotes Homeodomain-interacting Protein Kinase 2 (HIPK2) Accumulation and Activation in Response to DNA Damage.
Reuven N; Adler J; Porat Z; Polonio-Vallon T; Hofmann TG; Shaul Y
J Biol Chem; 2015 Jul; 290(27):16478-88. PubMed ID: 25944899
[TBL] [Abstract][Full Text] [Related]
11. PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains.
Möller A; Sirma H; Hofmann TG; Rueffer S; Klimczak E; Dröge W; Will H; Schmitz ML
Cancer Res; 2003 Aug; 63(15):4310-4. PubMed ID: 12907596
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo.
Kim EJ; Park JS; Um SJ
J Biol Chem; 2002 Aug; 277(35):32020-8. PubMed ID: 11925430
[TBL] [Abstract][Full Text] [Related]
13. Differential interactions of the homeodomain-interacting protein kinase 2 (HIPK2) by phosphorylation-dependent sumoylation.
Sung KS; Go YY; Ahn JH; Kim YH; Kim Y; Choi CY
FEBS Lett; 2005 Jun; 579(14):3001-8. PubMed ID: 15896780
[TBL] [Abstract][Full Text] [Related]
14. The crystal structure of the protein kinase HIPK2 reveals a unique architecture of its CMGC-insert region.
Agnew C; Liu L; Liu S; Xu W; You L; Yeung W; Kannan N; Jablons D; Jura N
J Biol Chem; 2019 Sep; 294(37):13545-13559. PubMed ID: 31341017
[TBL] [Abstract][Full Text] [Related]
15. Overlapping roles for homeodomain-interacting protein kinases hipk1 and hipk2 in the mediation of cell growth in response to morphogenetic and genotoxic signals.
Isono K; Nemoto K; Li Y; Takada Y; Suzuki R; Katsuki M; Nakagawara A; Koseki H
Mol Cell Biol; 2006 Apr; 26(7):2758-71. PubMed ID: 16537918
[TBL] [Abstract][Full Text] [Related]
16. PML tumor suppressor is regulated by HIPK2-mediated phosphorylation in response to DNA damage.
Gresko E; Ritterhoff S; Sevilla-Perez J; Roscic A; Fröbius K; Kotevic I; Vichalkovski A; Hess D; Hemmings BA; Schmitz ML
Oncogene; 2009 Feb; 28(5):698-708. PubMed ID: 19015637
[TBL] [Abstract][Full Text] [Related]
17. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2.
Hofmann TG; Möller A; Sirma H; Zentgraf H; Taya Y; Dröge W; Will H; Schmitz ML
Nat Cell Biol; 2002 Jan; 4(1):1-10. PubMed ID: 11740489
[TBL] [Abstract][Full Text] [Related]
18. HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage.
Di Stefano V; Soddu S; Sacchi A; D'Orazi G
Oncogene; 2005 Aug; 24(35):5431-42. PubMed ID: 15897882
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation-dependent control of Pc2 SUMO E3 ligase activity by its substrate protein HIPK2.
Roscic A; Möller A; Calzado MA; Renner F; Wimmer VC; Gresko E; Lüdi KS; Schmitz ML
Mol Cell; 2006 Oct; 24(1):77-89. PubMed ID: 17018294
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitination and degradation of homeodomain-interacting protein kinase 2 by WD40 repeat/SOCS box protein WSB-1.
Choi DW; Seo YM; Kim EA; Sung KS; Ahn JW; Park SJ; Lee SR; Choi CY
J Biol Chem; 2008 Feb; 283(8):4682-9. PubMed ID: 18093972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
